Sign in

NCT07660263Recruiting

Development of a Genomics-based Multimodal Prediction Model for Post-stroke Vascular Dementia

Development of a Genomics-based Multimodal Prediction Model for Post-stroke Vascular Dementia: An Ambidirectional Patient-Control Cohort Study

Source: ClinicalTrials.gov · Last updated 29 Jul 2026

Brief summary (registry, in English)

To collect large-scale multimodal data, including genomic information, neuroimaging, neurophysiological measures, cognitive assessments, and clinical characteristics from stroke survivors and healthy controls. This study aims to develop and validate an integrated prediction model for identifying individuals at high risk of post-stroke vascular dementia and to establish a foundation for precision medicine approaches in stroke-related cognitive impairment.

Status (registry)
Recruiting
Study type
Observational
Enrollment
300 (estimated)
First submitted
15 Jun 2026
Start date
24 Jul 2026
Primary completion date
31 Dec 2030
Lead sponsor
Seyoung Shin
Diseases
Stroke
NCT number
NCT07660263

What you commit to

  • Study type: Observational
  • Planned participants: 300
  • From 24 Jul 2026 to the primary completion date, 31 Dec 2030
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Stroke Patient Group:
    • Impaired ability to provide consent (MMSE \<10) without an accompanying caregiver or legally authorized representative.
    • History of dementia due to causes other than stroke (e.g., Alzheimer's disease) prior to stroke onset.
    • History of major neurological disorders affecting cognition prior to stroke onset (e.g., Parkinson's disease, brain tumor, multiple sclerosis).
    • Severe aphasia or impaired consciousness preventing completion of cognitive assessments.
    • Current or pre-stroke severe psychiatric disorders that may affect cognitive function (e.g., major depression, schizophrenia) or use of related medications.
    • Strong family history of hereditary cerebrovascular disorders (e.g., CADASIL).
    • Contraindication to MRI (e.g., metallic implants) or refusal to provide blood samples for genomic analysis.
    • Any condition that, in the opinion of the investigator, would make participation unsuitable.

Other illness

  • Healthy Control Group:
    • Current severe psychiatric disorders that may affect cognitive function (e.g., major depression, schizophrenia) or use of related medications.
    • Strong family history of hereditary cerebrovascular disorders (e.g., CADASIL).
    • Severe medical illness considered inappropriate for study participation.
    • Any condition that, in the opinion of the investigator, would make participation unsuitable.

Who the study is looking for

  • Healthy Control Group:
    • Adults aged 19 years or older.
    • Able to be age- and sex-matched to the stroke cohort.
    • No history of stroke, transient ischemic attack (TIA), or other central nervous system disorders.
    • Cognitive function within the normal range for age and education level based on screening assessments (K-MMSE and K-MoCA).
    • Able to understand the study procedures and provide written informed consent.
  • Stroke Patient Group:
    • Adults aged 19 years or older.
    • First-ever ischemic or hemorrhagic stroke confirmed by CT or MRI.
    • Enrolled in one of the following strata according to time since stroke onset:
    • Stratum A: 7 days to 3 months after stroke onset. Stratum B: \>3 months to 12 months after stroke onset. Stratum C: \>12 months to 36 months after stroke onset.
    • \- Able to understand the study procedures and provide written informed consent, or consent provided by a legally authorized representative when applicable.

Age in the registry: 19 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Bundang CHA Medical Center
Coordinator of this site? Confirm its status
Gyeonggi-doSouth KoreaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.